Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062125 · ClinicalTrials.gov registry record
Calcinosis in a Single-Center Scleroderma Population
A clinical trial of Scleroderma and Calcinosis, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 66
- Enrollment target
- 1
- Study location
NCT02062125 is a study of Scleroderma and Calcinosis that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 66 participants, below the 400-participant average among 23 other Scleroderma trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02062125, a study of Scleroderma and Calcinosis, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 10 year study of scleroderma patients with calcinosis 1) to better understand how common and if there are any risk factors for having calcinosis 2\) to identify common complications associated with scleroderma-related calcinosis. .
Conditions Studied
Study Locations (1)
New Jersey
- RWJ Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2012-10-31 |
| Est. Completion | 2024-03-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02062125
The ClinicalTrials.gov registry entry for NCT02062125 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 400-participant average among 23 other Scleroderma trials with a reported enrollment target (83% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Scleroderma appearing as the primary indexed condition, and to 0 interventions.
NCT02062125 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02062125 about?
NCT02062125 is a clinical study titled "Calcinosis in a Single-Center Scleroderma Population". This is a 10 year study of scleroderma patients with calcinosis 1) to better understand how common and if there are any risk factors for having calcinosis 2\) to identify common complications associated with scleroderma-related calcinosis. .
What is the current status of trial NCT02062125?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2012-10-31. Estimated completion is 2024-03-15.
What conditions does trial NCT02062125 study?
This clinical trial studies the following conditions: Scleroderma, Calcinosis.
Who is sponsoring clinical trial NCT02062125?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02062125 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.